Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | LGMN | Q99538 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | UGCG | Q16739 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465617 | 0.82 | KMT2A (0.48) | SLC6A4SLC6A3EPHX2SLC6A2 | |
| SCHEMBL2534042 | 0.81 | OPRL1 (0.50) | SLC6A4SLC6A3EPHX2SLC6A2LGMN | |
| SCHEMBL25010550 | 0.81 | EPHX2 (0.45) | SLC6A4SLC6A3EPHX2SLC6A2LGMN | |
| SCHEMBL3443934 | 0.81 | SLC6A4 (0.46) | SLC6A4SLC6A3EPHX2SLC6A2 | |
| SCHEMBL4446502 | 0.79 | THRB (0.50) | SLC6A4SLC6A3EPHX2SLC6A2HDAC3 | |
| SCHEMBL27925689 | 0.78 | SLC6A4 (0.47) | SLC6A4SLC6A3EPHX2SLC6A2 | |
| SCHEMBL4436038 | 0.76 | APP (0.45) | SLC6A3CYP3A4HDAC1 | |
| SCHEMBL19469594 | 0.76 | MEN1 (0.52) | SLC6A4SLC6A3EPHX2SLC6A2 | |
| SCHEMBL18742598 | 0.75 | OPRL1 (0.48) | SLC6A4SLC6A3EPHX2SLC6A2LGMN | |
| SCHEMBL3444085 | 0.75 | SLC6A4 (0.48) | SLC6A4SLC6A3EPHX2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134692-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | Wyeth a Corporation of the State of Delaware (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008121817-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | WYETH (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | VCAM1, ICAM1, SELE | SLC6A4 2916/4885SLC6A3 2680/4885EPHX2 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.